Actively Recruiting
Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma
Led by Centre Antoine Lacassagne · Updated on 2025-04-11
200
Participants Needed
1
Research Sites
469 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The hypothesis of this prospective observational pilot study of diagnostic diagnostic performance is that, for patients with NSCLC treated with immunotherapy associated or not with chemotherapy, certain metabolic biomarkers on 18FDG PET scans allow early identification of treatment response (or lack of response to treatment) and optimize prediction of tumor response compared with current standards.
CONDITIONS
Official Title
Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than or equal to 18 years
- Histologically confirmed metastatic or locally advanced NSCLC
- Indicated for immunotherapy (Nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab) with or without chemotherapy (carboplatin, cisplatin, pemetrexed, paclitaxel, nab-paclitaxel)
- Treatment prescribed and validated by a Multidisciplinary Team
- ECOG performance status between 0 and 3
- Patient understands the protocol and agrees orally
- Patient has not objected to use of their data for medical research
- Patient has social security coverage
You will not qualify if you...
- Age under 18 years
- Contraindications to 18FDG PET-CT (severe claustrophobia, unbalanced diabetes with fasting glucose ≥ 11 mmol)
- Hemoglobin less than 7 g/dL, or less than 9 g/dL if respiratory or cardiovascular disease
- Participation in other biomedical studies involving drugs, medical devices, or imaging techniques
- Refusal to participate in this study
- Contraindications to immunotherapy or chemotherapy (e.g., hypersensitivity to active substances or excipients)
- Vulnerable persons as defined by law, including pregnant or nursing women, persons deprived of liberty, those hospitalized without consent, or adults under legal protection unable to give consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Antoine Lacassagne
Nice, France, 06189
Actively Recruiting
Research Team
S
Study Coordinator
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here